Rationale: Acute kidney injury (AKI) has a high prevalence and mortality in critically ill patients. It is also a powerful risk factor for heart failure (HF) incidence driven by hemodynamic changes and neurohormonal activation. However, no drugs have been approved by the FDA. Endogenous particulate guanylyl cyclase A receptor (pGC-A) activators were reported to preserve renal function and improve mortality in AKI patients, while hypotension accompanied by pGC-A activators have limited their therapeutic potential. Objective: We investigated the therapeutic potential of a non-hypotensive pGC-A activator, CRRL269 in a short-term, large animal model of ischemia induced AKI and also investigated the potential of urinary C-type natriuretic peptide (uCNP) as a biomarker for AKI. Methods and Results: We first showed CRRL269 stimulated cGMP generation, suppressed plasma angiotensin II and reduced cardiac filling pressures without lowering blood pressure in the AKI canine model. We also demonstrated CRRL269 preserved glomerular filtration rate (GFR), increased renal blood flow (RBF) and promoted diuresis and natriuresis. Further, CRRL269 reduced kidney injury and apoptosis as evidenced by ex vivo histology and tissue apoptosis analysis. We also showed, compared to native pGC-A activators, CRRL269 is a more potent inhibitor of apoptosis in renal cells and induced less decreases in intracellular Ca 2+ concentration in vascular smooth muscle cells. The renal anti-apoptotic effects were at least mediated